AbbVie Inc. (4AB.DE) is set to report first-quarter 2026 earnings on April 29, 2026. The pharmaceutical giant operates in the healthcare sector as a major drug manufacturer. With a market cap of $315.99 billion and 1.77 billion shares outstanding, 4AB.DE trades at €175.00 per share. The stock has declined 1.07% recently and trades below its 50-day average of €187.92. Meyka AI rates 4AB.DE with a grade of B, suggesting a hold position. Investors await the earnings announcement to assess AbbVie’s pharmaceutical pipeline performance and cash flow generation.
Stock Performance and Valuation Metrics
AbbVie’s stock reflects mixed momentum heading into earnings. The stock trades at €175.00, down 1.07% from recent highs. Over the past month, 4AB.DE has declined 7.53%, though it remains up 17.22% over the past year.
Current Trading Levels
The stock’s 52-week range spans €147.60 to €207.00, placing current prices near the midpoint. Trading volume averages 536 shares daily, with recent volume at 343 shares. The price-to-earnings ratio stands at 88.44x, reflecting elevated valuation multiples typical of mature pharmaceutical companies with strong cash generation.
Dividend and Shareholder Returns
AbbVie maintains a dividend yield of 3.22%, with annual dividends per share at €6.77. The payout ratio reaches 2.76x, indicating the company returns substantial capital to shareholders. This high dividend yield attracts income-focused investors seeking stable returns from healthcare holdings.
Technical Position
The stock trades between Bollinger Band support at €172.35 and resistance at €187.17. The RSI at 44.57 suggests neutral momentum, while the ADX at 26.52 indicates a strong downtrend. The MACD histogram at -0.09 shows weakening momentum, signaling caution for near-term traders.
Financial Health and Profitability Analysis
AbbVie demonstrates solid profitability metrics despite recent earnings challenges. The company generates strong cash flows and maintains operational efficiency across its pharmaceutical portfolio.
Earnings and Margins
The trailing twelve-month EPS stands at €2.02, with a net profit margin of 6.91%. Operating margin reaches 31.60%, reflecting AbbVie’s pricing power in specialty pharmaceuticals. Gross profit margin of 73.36% shows strong product economics. However, net income declined 12.03% year-over-year, indicating pressure from patent expirations and competitive dynamics.
Cash Flow Generation
Operating cash flow per share reaches €10.74, while free cash flow per share stands at €10.55. The company converts 98.27% of operating cash flow into free cash flow, demonstrating efficient capital management. Operating cash flow declined 17.66% year-over-year, reflecting lower earnings and working capital changes.
Return Metrics
Return on assets stands at 3.15%, while return on capital employed reaches 21.31%. These metrics indicate AbbVie efficiently deploys capital in its pharmaceutical operations. The company’s interest coverage ratio of 6.75x shows comfortable debt service capacity.
Product Portfolio and Growth Drivers
AbbVie’s pharmaceutical portfolio spans multiple therapeutic areas with blockbuster drugs generating substantial revenue. The company’s earnings depend heavily on key product performance and pipeline advancement.
Key Therapeutic Areas
AbbVie’s portfolio includes HUMIRA for autoimmune diseases, SKYRIZI for psoriasis, and RINVOQ for rheumatoid arthritis. IMBRUVICA treats blood cancers, while VENCLEXTA addresses chronic lymphocytic leukemia. MAVYRET generates revenue from hepatitis C patients. These specialty drugs command premium pricing in developed markets.
Revenue and Growth Trends
Revenue per share reaches €34.52 on a trailing basis. Full-year revenue growth stands at 3.71%, indicating modest expansion. However, EBIT declined 23.01% year-over-year, reflecting patent cliff pressures and increased competition. Research and development spending grew 66.66%, showing AbbVie’s commitment to pipeline innovation.
Market Position
AbbVie maintains strong market positions in immunology, oncology, and virology. The company’s enterprise value of €435.56 billion reflects investor confidence in long-term cash generation. However, valuation multiples remain elevated relative to growth rates.
Meyka AI Analysis and Investment Outlook
Meyka AI rates 4AB.DE with a grade of B, suggesting a hold position for current shareholders. The rating reflects balanced risk-reward dynamics in the pharmaceutical sector.
Rating Components
The B grade incorporates multiple factors: sector comparison (16%), industry comparison (16%), financial growth (12%), and key metrics (16%). Analyst consensus and fundamental growth contribute 14% and 7% respectively. The rating suggests AbbVie offers reasonable value but lacks compelling upside catalysts.
Forward Guidance and Forecasts
Meyka’s price forecasts suggest modest upside potential. The monthly forecast targets €180.32, while the yearly forecast reaches €209.56. Three-year and five-year forecasts project €244.34 and €279.05 respectively. These targets imply 19.6% upside over twelve months, though execution risk remains.
Investment Considerations
Investors should monitor Q1 earnings for revenue trends, margin sustainability, and pipeline progress. The high dividend yield provides downside support, while patent expirations create headwinds. AbbVie’s ability to grow earnings through new product launches will determine stock performance.
Final Thoughts
AbbVie’s April 29, 2026 earnings report will test investor confidence amid patent cliff pressures and modest growth. The €175.00 stock price reflects elevated valuations, while the 3.22% dividend yield attracts income investors. Meyka AI’s B grade suggests a hold stance, balancing strong cash generation against margin compression risks. Forward guidance and pipeline updates are crucial to determine if AbbVie can accelerate earnings growth or continue facing headwinds in the competitive pharmaceutical sector.
FAQs
When does AbbVie report Q1 2026 earnings?
AbbVie reports Q1 2026 earnings on April 29, 2026. The announcement will include revenue, EPS, and forward guidance. Investors should monitor the earnings call for management commentary on product performance and pipeline progress.
What is the Meyka AI grade for 4AB.DE?
Meyka AI rates 4AB.DE with a grade of B, suggesting a hold position. The rating reflects balanced fundamentals, strong cash flow, and elevated valuation multiples. The grade incorporates sector, industry, and financial metrics analysis.
What is AbbVie’s dividend yield and payout ratio?
AbbVie offers a 3.22% dividend yield with annual dividends of €6.77 per share. The payout ratio reaches 2.76x, indicating the company returns substantial capital to shareholders. This high yield attracts income-focused investors.
How has AbbVie’s earnings trended recently?
AbbVie’s net income declined 12.03% year-over-year, while EBIT fell 23.01%. Operating cash flow dropped 17.66%, reflecting patent cliff pressures and competitive dynamics. Revenue grew modestly at 3.71%, indicating growth challenges.
What are Meyka’s price targets for 4AB.DE?
Meyka forecasts €180.32 monthly, €209.56 yearly, €244.34 in three years, and €279.05 in five years. These targets imply 19.6% upside over twelve months from current €175 levels, though execution risk remains.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)